Literature DB >> 18998134

Role of copper transporters in resistance to platinating agents.

Cara A Rabik1, Edward B Maryon, Kristen Kasza, John T Shafer, Catherine M Bartnik, M Eileen Dolan.   

Abstract

Copper transporters have been proposed to be involved in cellular import and export of platinating agents. Expression of the human copper transporter 1 (hCtr1) is thought to result in increased sensitivity to cisplatin, whereas expression of ATP7A and ATP7B are thought to be involved in resistance to cisplatin either by sequestering drug away from its targets (ATP7A) or by exporting the drug from the cell (ATP7B). In this study, we evaluated the sensitivity of cells expressing copper transporters to cisplatin, carboplatin and oxaliplatin. We also examined whether O (6)-benzylguanine, a modulator of platinating agent cytotoxicity, enhanced sensitivity of cells with or without the transporters to cisplatin. Overexpression of hCtr1 in the HEK293 cell line did not result in increased sensitivity to cisplatin, either alone or following treatment with O (6)-benzylguanine. In contrast, overexpression of ATP7A and ATP7B in Me32a fibroblasts resulted in increased resistance to cisplatin, but not to carboplatin or oxaliplatin. ATP7A-expressing cells (MeMNK) showed a significant enhancement of cisplatin cytotoxicity following O (6)-benzylguanine treatment, but ATP7B-expressing cells (MeWND) did not. Notably, expression of either ATP7A or ATP7B did not result in a change in total cytoplasmic platinum levels following treatment with BG plus cisplatin. The mechanism of BG enhancement of cisplatin cytotoxicity is not likely through regulation of copper transporters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998134      PMCID: PMC2733887          DOI: 10.1007/s00280-008-0860-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

1.  Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

Authors:  Goli Samimi; Kuniyuki Katano; Alison K Holzer; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

2.  Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.

Authors:  A Russo; W DeGraff; N Friedman; J B Mitchell
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

Authors:  M E Dolan; R C Moschel; A E Pegg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.

Authors:  Cara A Rabik; Melissa L Fishel; Julianne L Holleran; Kristen Kasza; Mark R Kelley; Merrill J Egorin; M Eileen Dolan
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

6.  Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.

Authors:  Melissa L Fishel; Shannon M Delaney; Lindsay D Friesen; Ryan J Hansen; Eleanor G Zuhowski; Robert C Moschel; Merrill J Egorin; M Eileen Dolan
Journal:  Mol Cancer Ther       Date:  2003-07       Impact factor: 6.261

7.  Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.

Authors:  Alison K Holzer; Kuniyuki Katano; Leo W J Klomp; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Authors:  Goli Samimi; Roohangiz Safaei; Kuniyuki Katano; Alison K Holzer; Myriam Rochdi; Mika Tomioka; Murray Goodman; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

9.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Authors:  R J Knox; F Friedlos; D A Lydall; J J Roberts
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

10.  The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Authors:  Alison K Holzer; Goli Samimi; Kuniyuki Katano; Wiltrud Naerdemann; Xinjian Lin; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2004-06-30       Impact factor: 4.436

View more
  13 in total

Review 1.  Human copper transporters: mechanism, role in human diseases and therapeutic potential.

Authors:  Arnab Gupta; Svetlana Lutsenko
Journal:  Future Med Chem       Date:  2009-09       Impact factor: 3.808

Review 2.  ATP7A-related copper transport diseases-emerging concepts and future trends.

Authors:  Stephen G Kaler
Journal:  Nat Rev Neurol       Date:  2011-01       Impact factor: 42.937

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.

Authors:  Kristin D Ivy; Jack H Kaplan
Journal:  Mol Pharmacol       Date:  2013-03-29       Impact factor: 4.436

5.  Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.

Authors:  Xiang-Lin Tan; Ann M Moyer; Brooke L Fridley; Daniel J Schaid; Nifang Niu; Anthony J Batzler; Gregory D Jenkins; Ryan P Abo; Liang Li; Julie M Cunningham; Zhifu Sun; Ping Yang; Liewei Wang
Journal:  Clin Cancer Res       Date:  2011-07-20       Impact factor: 12.531

6.  Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.

Authors:  Akiko Morimoto; Satoshi Serada; Takayuki Enomoto; Ayako Kim; Shinya Matsuzaki; Tsuyoshi Takahashi; Yutaka Ueda; Kiyoshi Yoshino; Masami Fujita; Minoru Fujimoto; Tadashi Kimura; Tetsuji Naka
Journal:  Oncotarget       Date:  2014-09-15

Review 7.  Menkes disease: what a multidisciplinary approach can do.

Authors:  Rahul Ojha; Asuri N Prasad
Journal:  J Multidiscip Healthc       Date:  2016-08-17

8.  Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line.

Authors:  Lili Yang; Chunjuan Du; Lei Wu; Jinpu Yu; Xiumei An; Wenwen Yu; Shui Cao; Hui Li; Xiubao Ren
Journal:  J Cancer       Date:  2017-09-16       Impact factor: 4.207

Review 9.  Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.

Authors:  Yu-Hsuan Lai; Chin Kuo; Macus Tien Kuo; Helen H W Chen
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

10.  Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels.

Authors:  Qiang Wang; Jianchang Wei; Chengxing Wang; Tong Zhang; Di Huang; Fang Wei; Feng He; Wensong Cai; Ping Yang; Shanqi Zeng; Wanglin Li; Jie Cao
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.